Protection of Trigonelline on Experimental Diabetic Peripheral Neuropathy

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Group</td><td align="center">SOD (U/mL)</td><td align="center">Malonaldehyde (nmol/mL)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Control</td><td align="center">124.04 ± 4.46</td><td align="center">4.19 ± 0.78</td></tr><tr><td align="left">Diabetes</td><td align="center">83.94 ± 3.31*</td><td align="center">6.07 ± 0.97*</td></tr><tr><td align="left">Diabetes + trigonelline</td><td align="center">115.30 ± 7.87<sup>#</sup></td><td align="center">4.57 ± 0.95<sup>#</sup></td></tr><tr><td align="left">Diabetes + sitagliptin</td><td align="center">97.99 ± 4.95</td><td align="center">5.91 ± 1.41</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>Data are given as mean ± SD,<i> n</i> = 10. *<i>P</i> &lt; 0.01, compared with control rats; <sup>#</sup><i>P</i> &lt; 0.01, compared with diabetes rats.<br/></td></tr></table>

Effects of trigonelline on SOD activity and malonaldehyde content in serum.

Evidence-Based Complementary and Alternative Medicine

tab4

Table 4

Table 4: Protection of Trigonelline on Experimental Diabetic Peripheral Neuropathy 